WO2003063763A3 - Complement mediated assays for in vivo and in vitro methods - Google Patents

Complement mediated assays for in vivo and in vitro methods Download PDF

Info

Publication number
WO2003063763A3
WO2003063763A3 PCT/US2002/016302 US0216302W WO03063763A3 WO 2003063763 A3 WO2003063763 A3 WO 2003063763A3 US 0216302 W US0216302 W US 0216302W WO 03063763 A3 WO03063763 A3 WO 03063763A3
Authority
WO
WIPO (PCT)
Prior art keywords
vivo
complement mediated
vitro methods
mediated assays
complement
Prior art date
Application number
PCT/US2002/016302
Other languages
French (fr)
Other versions
WO2003063763A2 (en
Inventor
Elliot R Ramberg
Original Assignee
Cygene Inc
Elliot R Ramberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygene Inc, Elliot R Ramberg filed Critical Cygene Inc
Priority to AU2002365902A priority Critical patent/AU2002365902A1/en
Priority to EP02806678A priority patent/EP1506314A4/en
Priority to JP2003563459A priority patent/JP2005516198A/en
Priority to CA002447892A priority patent/CA2447892A1/en
Publication of WO2003063763A2 publication Critical patent/WO2003063763A2/en
Publication of WO2003063763A3 publication Critical patent/WO2003063763A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to methods and compositions for detection of target analytes, comprising proteins and nucleic acids, in multiple cellular compartments. Preferred embodiments comprise the use of complement-mediated assays and complement mediated treatments for human and animals. Methods and compositions for monitoring multiple stages of disease and infection are presented.
PCT/US2002/016302 2001-05-22 2002-05-22 Complement mediated assays for in vivo and in vitro methods WO2003063763A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002365902A AU2002365902A1 (en) 2001-05-22 2002-05-22 Complement mediated assays for in vivo and in vitro methods
EP02806678A EP1506314A4 (en) 2001-05-22 2002-05-22 Complement mediated assays for in vivo and in vitro methods
JP2003563459A JP2005516198A (en) 2001-05-22 2002-05-22 Complement-mediated assays for in vivo and in vitro methods
CA002447892A CA2447892A1 (en) 2001-05-22 2002-05-22 Complement mediated assays for in vivo and in vitro methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29261601P 2001-05-22 2001-05-22
US60/292,616 2001-05-22
US29732101P 2001-06-11 2001-06-11
US60/297,321 2001-06-11
US32402901P 2001-09-21 2001-09-21
US60/324,029 2001-09-21

Publications (2)

Publication Number Publication Date
WO2003063763A2 WO2003063763A2 (en) 2003-08-07
WO2003063763A3 true WO2003063763A3 (en) 2004-12-09

Family

ID=27670579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016302 WO2003063763A2 (en) 2001-05-22 2002-05-22 Complement mediated assays for in vivo and in vitro methods

Country Status (5)

Country Link
EP (1) EP1506314A4 (en)
JP (1) JP2005516198A (en)
AU (1) AU2002365902A1 (en)
CA (1) CA2447892A1 (en)
WO (1) WO2003063763A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056456A2 (en) * 2000-02-02 2001-08-09 Cygene, Inc. Methods and compositions for detection of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUHL ET AL: "A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTC-labeled anti-carcinoembryonic antigen antibody by a two-step approach", CANCER RESEARCH, vol. 55, no. SUPPL., December 1995 (1995-12-01), pages 5749S - 5755S, XP000872898 *
See also references of EP1506314A4 *

Also Published As

Publication number Publication date
AU2002365902A1 (en) 2003-09-02
CA2447892A1 (en) 2003-08-07
EP1506314A2 (en) 2005-02-16
JP2005516198A (en) 2005-06-02
EP1506314A4 (en) 2005-08-24
WO2003063763A2 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
EP1777234A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
JP2002531055A5 (en)
WO2002084250A3 (en) Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
WO2002036771A3 (en) Imaging, diagnosis and treatment of disease
DE69819124D1 (en) LYOPHILIZATION OF CULTIVATED, HUMAN CELLS FOR THE PRESERVATION OF RNA AND DNA
ATE353366T1 (en) NUCLEIC ACID AND PROTEIN, CALLED 158P1D7, FOR THE TREATMENT AND DETECTION OF BLADDER CANCER AND OTHER TYPES OF CANCER
WO2001056456A3 (en) Methods and compositions for detection of disease
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell
CA2334520A1 (en) Treatment of immune diseases
WO2002014361A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
DK1165102T3 (en) Matrix protein preparations for grafting in non-mineralized tissue
WO2003063763A3 (en) Complement mediated assays for in vivo and in vitro methods
EP2088197A3 (en) Haemophilus influenzae antigens and corresponding DNA fragments
EP1921451A3 (en) Complement mediated assays for in vivo and in vitro methods
WO2004072263A3 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2004058986A3 (en) Btl-ii nucleic acids, proteins, and antibodies
ATE403716T1 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN 85P1B3, USEFUL FOR TREATING AND DETECTING CANCER DISEASES
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2447892

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003563459

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002806678

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002806678

Country of ref document: EP